Skip to main content
Premium Trial:

Request an Annual Quote

Power3, Methodist Hospital Partner on Biomarker-Based Blood Tests for Neurodegenerative Disease

NEW YORK, July 19 (GenomeWeb News) - Power3 Medical Products and the Methodist Hospital Research Institute have partnered to search for protein biomarkers and develop a suite of tests for the diagnosis of neurodegenerative disease, Power3 said today.

 

In collaboration with Stan Appel, chair of neurology at Methodist Neurological Institute, Power3 has completed clinical validation by testing serum proteins from more than 600 patients with Lou Gehrig's, Alzheimer's, and Parkinson's disease.

 

Power3 said that it continues to evaluate serum from patients and plans to publish results from the study later this year.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.